BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31870724)

  • 1. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.
    Sun J; Zhang Z; OuYang J
    Urol Oncol; 2020 May; 38(5):401-409. PubMed ID: 31870724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
    Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
    Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
    Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
    Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
    Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
    J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
    Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
    Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
    Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
    Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.
    Wang NN; Zhou SR; Chen L; Tibshirani R; Fan RE; Ghanouni P; Thong AE; To'o KJ; Ghabili K; Nix JW; Gordetsky JB; Sprenkle P; Rais-Bahrami S; Sonn GA
    Urol Oncol; 2021 Dec; 39(12):831.e19-831.e27. PubMed ID: 34247909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.
    Zhou ZH; Liu F; Wang WJ; Liu X; Sun LJ; Zhu Y; Ye DW; Zhang GM
    Asian J Androl; 2021; 23(1):41-46. PubMed ID: 32503957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
    He BM; Shi ZK; Li HS; Lin HZ; Yang QS; Lu JP; Sun YH; Wang HF
    Ann Surg Oncol; 2020 Apr; 27(4):1284-1295. PubMed ID: 31848822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective validation of a nomogram predictive of a positive initial prostate biopsy].
    Ramírez-Backhaus M; Bahilo P; Arlandis S; Santamaría Navarro C; Pontones Moreno JL; Jiménez-Cruz F
    Actas Urol Esp; 2010 Jan; 34(1):35-42. PubMed ID: 20223131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
    Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy.
    Wu Q; Li F; Yin X; Gao J; Zhang X
    Medicine (Baltimore); 2021 Dec; 100(50):e28196. PubMed ID: 34918677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging.
    Martini A; Gupta A; Cumarasamy S; Lewis SC; Haines KG; Briganti A; Montorsi F; Tewari AK
    Int J Urol; 2019 Apr; 26(4):458-464. PubMed ID: 30659663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.
    van Leeuwen PJ; Hayen A; Thompson JE; Moses D; Shnier R; Böhm M; Abuodha M; Haynes AM; Ting F; Barentsz J; Roobol M; Vass J; Rasiah K; Delprado W; Stricker PD
    BJU Int; 2017 Dec; 120(6):774-781. PubMed ID: 28207981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy: A STROBE-compliant study.
    Huang TB; Mao SY; Lu SM; Yu JJ; Luan Y; Gu X; Liu H; Zhou GC; Ding XF
    Medicine (Baltimore); 2016 Nov; 95(44):e5307. PubMed ID: 27858908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer.
    Xie W; Xu Z; Qiu Y; Ye W; Zhang Z; Wang C; Zang J
    Biomed Res Int; 2023; 2023():9936087. PubMed ID: 36685670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.